PREVENTION OF AN INFLUENZA PANDEMIC IN MEXICO- ESTABLISHING A COST-EFFECTIVE ALTERNATIVE FOR ELDERLY POPULATION
Author(s)
Baca-Muro VI1, Soria-Cedillo IF2, Olvera K3, Garcia-Contreras F41Research Consulting, Puebla, Mexico, 2Research Consulting, Hacienda Ojo de Agua, Mexico, 3Novartis Farmaceutica México, Mexico D.F., Mexico, 4Instituto Mexicano de Seguro Social, Mexico D.F., Mexico
OBJECTIVES: To determine the most cost-effective alternative for influenza prevention in Mexican elderly population in a pandemic case scenario. METHODS: A cost-effectiveness study was performed with Mexican Public Health Institution perspective comparing the use of MF59-adjuvanted vaccine (MF59), split vaccine (SPL) and a No Vaccination Program Alternative (NOVA). A systematic review of literature was designed in order to evaluate the effectiveness of MF59 and SPL measured as hemagglutination-inhibition antibody titers against A/H1N1 strain, and to calculate the influenza incidence in a pandemic case scenario. A cost matrix was calculated considering vaccines, vaccination program, medical visits, influenza and influenza related complications treatment, hospitalization and intensive care unit cost. Different proportions of patients with influenza were considered to determine complications related to the disease. Use of resources for complication treatment was assumed to be the same for every alternative evaluated. A decision tree was designed to simulate the use of resources. Results were evaluated with incremental analysis and sensitivity analysis of the most uncertain variables (influenza incidence, vaccine effectiveness, percentage of patients developing complications related to influenza) in order to establish robustness of the study. RESULTS: The use of MF59 represents the lowest cost per patient avoiding influenza or complications related to influenza when compared with the use of SPL or NOVA (MF59: US$25.17; SPL: US$40.50; NOVA: US$127.27) due to reduced institutional expenses. The ICER shows that MF59 is a dominant alternative in prevention of influenza and its complications while the sensitivity analysis exhibits robustness for the base study. CONCLUSIONS: MF59 is the most cost-effective alternative in influenza prevention for elderly population when a pandemic case scenario in Mexico is simulated. The use of MF59 represents savings estimated in US$15.32 and US$102.10 per patient avoiding influenza when compared to SPL and NOVA, respectively.
Conference/Value in Health Info
2009-10, ISPOR Europe 2009, Paris, France
Value in Health, Vol. 12, No. 7 (October 2009)
Code
PIN41
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine)